Abstract 857
Background
Colonoscopy is recommended as preferred test for first-degree relatives (FDRs) of colorectal cancer (CRC) patients. However, colonoscopy screening rate remains low. A systematic review and meta-analysis conducted by the research team show that tailored communication is an effective approach to increase uptake of colonoscopy. However, the decision rules that guide the tailored process remain unclear. Based on the identified evidences, a mHealth intervention with an integrated tailoring decision system was developed. This study aimed to test the feasibility and acceptability of this mHealth intervention in Chinese FDRs.
Methods
A single-blinded, family-based cluster randomized controlled trial was conducted. 20 families with CRC patients were randomized to intervention (10 families, n = 11) or control group (10 families, n = 10). Intervention consists of 3 sessions that provided tailored cancer and screening messages on response of personal assessment. All participants received an e-brochure on CRC and CRC screening. Feasibility was measured by recruitment and completion rate, whereas acceptability was assessed by a self-developed questionnaire.
Results
34.5% of eligible family members agreed to participate. 70% of participants completed the trial and all of them completed 3 sessions. All the participants satisfied with the intervention, and agreed the intervention help them understand their risks and appropriate screening recommendations. The main reason for low recruitment rate is that cancer cases were contacted through phone to identify FDRs. Even this is a common strategy when conducting family trials, it is difficult to obtain the trust of FDRs by phone due to the adverse influence of phone scam.
Conclusions
It is acceptable to provide mHealth intervention to Chinese FDRs. However, family recruitment utilizing cancer registry-identified cases seems less feasible in Chinese population. Recruitment through direct contact with FDRs is recommended, for example, through current screening program or clinical units. Furthermore, a definitive trial to test the effectiveness of developed intervention is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bai Yang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract